NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- Preclinical Imaging (In-VIVO) Market is expected to reach 1336.13 million by 2026 at CAGR of 4.92%. Preclinical imaging is medical process of visualization of living animals for purpose of research, such as new medical procedure and drug development. In vivo imaging has been described as bridging the gap between in vitro exploratory and in vivo clinical research, facilitating the direct and fast transfer of preclinical studies on animal models to clinical investigation in man. Imaging modalities have long been crucial to the researcher in observing changes, either at the organ, tissue, cell, or molecular level, in animals responding to physiological or environmental changes. 

In application aspect, vivo imaging is increasingly deployed across the drug development process, with applicability in target identification, compound optimisation and pre-Phase I studies. In vivo imaging has been described as bridging the gap between in vitro exploratory and in vivo clinical research, facilitating the direct and fast transfer of preclinical studies on animal models to clinical investigation in man. The key diseases/therapeutic areas targeted with in vivo preclinical imaging by survey respondents were oncology/cancer (70% targeting). This was followed by inflammatory disease/autoimmune (36% targeting), neurology / CNS / neurodegeneration/ pain (32% targeting) and then cardiovascular (25% targeting). 

Imaging modalities that are non-invasive and in vivo have become especially important to study animal models longitudinally. The most suitable modalities for small-animal in vivo imaging applications are based on nuclear medicine techniques (essentially, positron emission tomography [PET] and single photon emission computed tomography [SPECT]), optical imaging (OI), computed tomography (CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy imaging (MRSI), and ultrasound.

Get Free Sample: https://www.profsharemarketresearch.com/sample/preclinical-imaging-in-vivo-market-report-sample/

Preclinical Imaging (In-VIVO) Market: Competitive Analysis

Report includes accurate analysis of key players with Market Value, Company profile, SWOT analysis. The Study constitutes of following key players in Preclinical Imaging (In-VIVO) Market:

• PerkinElmer
• Bruker Corporation
• FUJIFILM Holdings
• Mediso
• MILabs B.V.
• MR Solutions
• Aspect Imaging
• LI-COR Biosciences
• Trifoil Imaging
• Miltenyi Biotec

Preclinical Imaging (In-VIVO) Market: Techniques Type

• MRI (Magnetic Resonance Imaging)
• PET (Positron Emission Tomography)
• SPECT (Single Photon Emission Computed Tomography)
• Micro-CT (Micro Computed Tomography)
• Optical imaging and Magnetic particle (MPI)

Get Free Customized Report Sample: https://www.profsharemarketresearch.com/enquiry/preclinical-imaging-in-vivo-market-report-enquiry/

Preclinical Imaging (In-VIVO) Market: Vessel Type

• Oncology
• Neurology
• Cardiology
• Inflammation
• Infectious diseases
• Cancer research
• Functional and Anatomical Neuroimaging
• Orthopedics
• Cardiac imaging
• Stroke models

Preclinical Imaging (In-VIVO) Market report delivers comprehensive analysis of:

• Market Forecast for 2018-26
• Market growth drivers
• Challenges and Opportunities
• Emerging and Current market trends
• Market player Capacity, Production, Revenue (Value)
• Supply (Production), Consumption, Export, Import analysis
• End user/application Analysis

Buy Report: https://www.profsharemarketresearch.com/buy/preclinical-imaging-in-vivo-market-report-buy-su/

Contact Us:

Mia Cox,

Email- sales@profsharemarketresearch.com

Tel- 1-877-797-7295

www.profsharemarketresearch.com